Background. Botulism is a rare, potentially fatal paralytic illness caused by neurotoxins. To inform the evaluation of patients with suspected botulism, we conducted a systematic review to describe the clinical features of botulism.
Botulism is a rare, potentially fatal paralytic illness caused by neurotoxins produced by Clostridium botulinum and infrequently by Clostridium butyricum and Clostridium baratii. Persons are exposed to botulinum neurotoxins by ingestion of preformed toxin (foodborne botulism), by colonization of a wound (wound botulism) or the gastrointestinal tract (infant botulism and adult intestinal colonization botulism) by neurotoxin-producing Clostridium species, or through cosmetic or therapeutic injection (iatrogenic botulism) [1] . Of the 7 botulinum toxin types (designated by letters A-G), human disease is most frequently associated with types A, B, or E and rarely with type F [2] . Toxin-induced weakness typically begins in the cranial nerves (eg, diplopia, dysarthria) then progresses to the extremities in a proximal to distal manner. This descending paralysis can impair respiratory muscles, causing respiratory failure and death, but it has generally been thought that extremity weakness precedes respiratory distress or failure [2] .
Early clinical diagnosis of botulism is critical because (1) paralysis can progress quickly to respiratory failure and (2) early administration of botulinum antitoxin may arrest progression of paralysis and prevent respiratory failure [3] .
Large unintentional foodborne botulism outbreaks occur periodically [4] [5] [6] . Furthermore, several nations have reportedly weaponized botulinum toxin for biological warfare, and botulinum toxin could potentially be deployed by the foodborne or aerosolized route to cause an intentional outbreak [7, 8] . To improve recognition of the range of signs and symptoms in sporadic cases and outbreaks so botulism patients are treated in a timely manner, we systematically reviewed the literature to describe the clinical features of botulism: signs and symptoms of botulism reported at hospital admission; incubation period and duration of illness before hospital admission; and patientlevel factors associated with respiratory failure and death.
METHODS

Data Sources and Search String
Botulism experts and librarians developed a search strategy using terms such as "botulism" and "Clostridium botulinum. " We searched Medline Ovid (1946-), Embase Dialog , Embase Ovid (1988-), Cumulative Index to Nursing and Allied Health Literature EBSCO (1981-), Global Health Ovid (1910-), Cochrane Library (1800-), Scopus (1960-), and ClinicalTrials.gov for English language articles through May 2015 (Supplementary Table 1 ). In addition, we manually searched Morbidity and Mortality Weekly Report (MMWR) editions published before 1980. The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in PROSPERO (number CRD42015024784) [9] .
Study Selection
We considered articles in English with the variables of interest, including signs and symptoms reported at hospital admission. Review articles, duplicate reports, and nonpublished case reports or case series were excluded. Two authors independently screened titles and abstracts to identify reports warranting fulltext review based on article type and likelihood of containing patient-level data. In the event that title-abstract review yielded discrepant judgement on the need for full-text review, a fulltext review was completed. The types of articles identified and included were case reports and case series.
We defined cases as hospitalized, nonpregnant adults (ie, ≥18 years of age) with confirmed foodborne or wound botulism who reportedly had ≥1 sign or symptom consistent with botulism, including features such as cranial nerve palsies (eg, diplopia, dysphagia), extremity weakness, and shortness of breath. Pregnant women were included in a separate review [10] . Botulism could be confirmed in any of 3 ways-by laboratory confirmation, epidemiologic link, or association with an outbreak. Laboratory confirmation includes (1) identification of botulinum toxin in serum, gastric fluid, stool, or food consumed by the affected patient or (2) isolation of neurotoxin-producing Clostridium species, such as C. botulinum, C. butyricum, or C. baratii in stool or a wound of an affected patient. If laboratory results were difficult to interpret, Centers for Disease Control and Prevention (CDC) botulism laboratory experts were consulted. If a patient consumed the same food vehicle as a patient who had laboratory-confirmed botulism, the patient was confirmed by epidemiologic link, similar to existing case definitions used in public health practice [11] . Cases in a botulism outbreak were confirmed by the epidemiologic association with the outbreak, even in the absence of laboratory confirmation.
Data Abstraction
We abstracted the following variables as available: author, title, year of publication, patient demographics, time from exposure to illness onset (ie, incubation period), time from illness onset to hospital admission, signs and symptoms reported up to and at the time of hospital admission, laboratory tests, timing and duration of intubation, antitoxin administration, and patient survival. Illness onset was defined as the onset of neurological signs or symptoms. Incubation period data were only abstracted for foodborne cases because the exact time of exposure for wound botulism is unknown in many cases. After initial data abstraction, 1 of 3 review authors (K. C. S., S. F. D., D. M. D.) independently re-reviewed the article and confirmed that data abstracted by the first reviewer were correct. Data discrepancies were resolved by consensus of the reviewers at weekly conferences. Data was abstracted into a Microsoft Access 2013 database (Microsoft Corporation, Redmond, Washington).
Data Synthesis and Analyses
The initial hospital day was defined as the day of reported admission, and cranial nerve involvement was defined as diplopia, blurry vision, extraocular palsy, dilated pupils, ptosis, facial paralysis, slurred speech, dysarthria, dysphagia, dysphonia, impaired gag, or neck weakness. Respiratory involvement was defined as shortness of breath, dyspnea, or respiratory distress or failure. We analyzed the median incubation period and time from illness onset to hospital admission and dichotomized these intervals as <48 hours or ≥48 hours. We categorized cases as outbreak-associated (≥2 cases) or as sporadic (single case not linked to an outbreak).
We summarized and compared the frequency of signs, symptoms, and outcomes using χ 2 tests and incubation period and time from illness onset to hospital admission using Wilcoxon-MannWhitney tests, with statistical significance defined as P < .05. We stratified analyses of incubation period and time from illness onset to hospital admission by toxin type, respiratory distress or failure at hospital admission, and death. We entered variables associated with respiratory distress or failure in bivariate analyses (defined as P < .15) in a stepwise Firth logistic regression model investigating clinical and epidemiologic characteristics associated with respiratory distress or failure at hospital admission. We conducted the descriptive analysis using SAS software version 9.4 (SAS Institute, Cary, North Carolina) and the logistic regression model using R version 3.3.2.
Level of Certainty and Completeness
We modified the Newcastle-Ottawa Scale to assess the quality of the case reports and case series included in the analysis [12] . Using the modified tool, 2 reviewers (S. F. D., S. A.) assigned each case 0-11 stars based on criteria such as report of patient outcome. We also calculated a completeness score for each case based on whether the authors reported 12 key variables (eg, extremity weakness). The description of each patient was categorized as detailed and precise (10-12 points), somewhat detailed (7-9.5 points), or cursory (1-6.5 points).
RESULTS
We identified Table 2 ). The US cases were reported from 32 states and Puerto Rico, with 62 (25%) cases reported in California. Approximately half of patients were men, and the median age was 41 years (range, 18-80 years). Most (86%) patients had foodborne botulism and most cases (65%) were associated with a foodborne outbreak. Toxin type A was the most frequently reported toxin type (Table 1) . Among the 171 foodborne botulism cases with available data, the median reported incubation period was 1 day (range, 0.1-12 days); the shortest reported incubation period was 2 hours [13] . Among the 185 foodborne and wound botulism cases with available data, the median reported time from illness onset to hospital admission was 2 days (range, 0.1-14 days). Table 2 shows the signs and symptoms most commonly reported at hospital admission. Nausea was reported for 123 (36%) foodborne patients vs 3 (5%) wound patients (P < .0001), and vomiting was reported for 172 (50%) foodborne patients vs 3 (5%) wound patients (P < .0001). Weakness or paralysis of at least 1 cranial nerve at admission was reported for 375 (93%) patients. Among these 375, 126 (34%) had 1-2 cranial nerve signs or symptoms, 119 (32%) had 3-4 cranial nerve signs or symptoms, and 130 (35%) had ≥5 cranial nerve signs or symptoms at admission.
Cranial nerve involvement at admission was not reported for 27 (7%) patients-24 patients with foodborne botulism and 3 patients with wound botulism. Among these 27, there were 22 admitted with gastrointestinal signs and symptoms (eg, nausea, vomiting), 4 admitted with respiratory signs and symptoms (eg, shortness of breath), and 1 admitted with subjective weakness. Among the 22 patients who were admitted with gastrointestinal features, 10 reportedly developed cranial nerve palsies after the day of admission, 9 did not have any report of the presence or absence of cranial nerve palsies, and 3 reportedly did not develop cranial nerve palsies. The 4 patients admitted with respiratory features reportedly developed cranial nerve palsies on hospital day 2 or 3. The patient admitted with subjective weakness reportedly developed cranial nerve palsies sometime after the day of admission.
At hospital admission, shortness of breath or dyspnea was reported for 50 (12%) patients and respiratory distress or failure for 119 (30%) patients. Among these 169 patients with respiratory involvement, defined as shortness of breath, dyspnea, or respiratory distress or failure, 71 (42%) had no report of extremity weakness. Patients with respiratory involvement at hospital admission had a shorter reported median incubation period (1 day; range, 0.1-12 days) than patients without respiratory involvement (1.5 days; range, 0.3-5 days) (P < .01). The median reported time from illness onset to hospital admission of 2 days did not differ based on respiratory involvement at hospital admission. Among the 130 patients with respiratory involvement at hospital admission and who had illness duration data, 77 (59%) had a reported time from illness onset to hospital admission of <48 hours. A total of 184 (46%) patients were reportedly intubated during their hospitalization. Of these, 154 had the hospital day of intubation reported, and 134 (87%) were intubated during the first 2 hospital days. The median reported duration of mechanical ventilation for the 70 patients with available data was 26.5 days (range, 1-298 days). The proportion of intubated patients by toxin type was as follows: type A, 63% (n = 94/150); type B, 42% (n = 29/69); type E, 35% (n = 28/79); and type F, 100% (n = 4/4). Figure 2 shows the publication year among the 101 (25%) patients who reportedly died during hospitalization. Most (n = 84/101; 83%) deaths occurred before 1980, and the case-fatality ratio was 40% during 1932-1979 compared with 9% during 1980-2015 (P < .01). The age groups with the highest case-fatality ratios were age 70-80 years, 44% (n = 8/18); 50-59 years, 34% (n = 19/56); and 18-29 years, 26% (n = 39/151). The median day of death was the third day of hospitalization (range, 1-120 days). Patients who died had a shorter reported median incubation period (1 day; range, 0.2-8 days) than patients who survived (1.5 days; range, 0.1-12 days) (P < .01). Similarly, patients who died had a shorter reported median time from illness onset to hospital admission (1 day; range, 0.1-5 days) than patients who survived (2 days; range, 0.1-14 days) (P = .02). Among the 101 patients who died, 68 had toxin type reported: type A, 22% (n = 33/150); type B, 16% (n = 11/69); type E, 30% (n = 24/79); and type F, 0% (n = 0/4). Table 3 shows incubation period, time from illness onset to hospital admission, respiratory and intubation status, and death by botulinum toxin type. Of the patients who reportedly received botulinum antitoxin, 86% (n = 229/267) survived compared with 53% (n = 72/135) who did not receive antitoxin (P < .0001). In the logistic regression model with respiratory distress or failure as the outcome, patients with toxin types A (odds ratio [OR], 3.3; 95% CI, 1.6-7.3), E (OR, 3.8; 95% CI, 1.7-9.3), or F (OR, 18.2; 95% CI, 2.3-226) had greater odds of presenting with respiratory distress or failure than patients with type B. Compared to women, men had lower odds of presenting with respiratory distress or failure (OR, 0.6; 95% CI, .4-.9). The presence of ptosis (OR, 1.7; 95% CI, 1.03-2.8), ocular palsies (OR, 2.5; 95% CI, 1.4-4.6), and abnormal deep tendon reflexes (OR, 2.3; 95% CI, 1.1-5) were statistically significantly associated with respiratory distress or failure.
The median score from the modified Newcastle Ottawa Scale was 7 (range, 3-9) and the median completeness score was 9 (range, 2.5-12). Table 1 shows the completeness score categories, with most cases rating as "somewhat detailed" or "cursory. "
DISCUSSION
This systematic review characterizes the range of signs and symptoms present at hospital admission and highlights the frequency and rapidity with which botulism patients may experience respiratory distress or failure and require hospitalization and intubation. Respiratory distress or failure is not always a late sign in botulism, and extremity weakness does not always precede respiratory involvement. Clinicians and public health officials should recognize the clinical features of botulism, the potential for rapid progression, and the fact that respiratory involvement can occur in a substantial proportion of patients within 2 days of illness onset.
The median incubation period is similar to the 18-36 hours (range, 6 hours-10 days) reported previously for foodborne botulism [7, 14] . A shorter incubation period may result from exposure to higher toxin doses and be a marker of disease severity, as patients who died had shorter median incubation periods than patients who survived. Similar to Woodruff et al, we found that a greater proportion of type A patients required intubation compared to type B and E cases; all 4 of the type F cases were intubated [15] . Patients with respiratory involvement at hospital admission did not experience a longer illness duration before hospital admission than those without respiratory involvement. Therefore, a longer duration of clinical illness does not appear to be the reason for respiratory involvement and the need for intubation. Toxin type and dose, receipt of botulism antitoxin, and patient-level factors have previously been shown to influence incubation period, severity of disease, and hospitalization [3, 15, 16] .
Gastrointestinal signs and symptoms, such as nausea and vomiting, were commonly reported, but their cause in foodborne botulism is unknown. Nausea and vomiting may result from C. botulinum, botulinum toxin, other substances, or other bacteria in food. The cause of nausea and vomiting in the small proportion of wound botulism cases is also unknown; potential reasons include drug or alcohol use, botulism-induced ileus, underlying comorbidity, diplopia, or a coinfection (eg, bacteremia, pneumonia). All cases included in this review were from unintentional botulism; it is not known if exposure to purified toxin, which might occur in an intentional exposure from a bioterrorism event, would produce gastrointestinal signs or symptoms [1] . Chertow et al describe 4 patients who were exposed to highly concentrated, purified botulinum toxin and had severe neurological illness but no gastrointestinal features [17] . Certain cranial nerve signs and symptoms reported as common in the botulism literature, such as ocular palsy, dysphonia, and dilated pupils, were reported in ≤25% of cases at hospital admission in our analysis [14] . More than one-third of patients had 1-2 cranial nerve palsies reported at hospital admission, highlighting the variability of illness at presentation and the need for clinicians to consider botulism in any patient presenting with cranial nerve palsies and no clear alternative diagnosis.
This systematic review has several limitations. All data were extracted from case reports and cases series and were dependent on author reporting of signs and symptoms. All clinical signs and symptoms may not have been recognized, recorded, or reported and, therefore, this review likely underestimates the true frequency of signs and symptoms in botulism patients, particularly those that are more subtle. The absence of a sign or symptom in a case report may indicate that the clinical finding was not present, that it was present but not detected, that it was detected but not documented in the medical chart, or that the author chose not to report it. Exact times for exposure, illness onset, and hospital admission were sometimes not reported, so we frequently abstracted time data as days instead of hours. Interpretation of data related to intubation is limited by authors frequently not reporting the reason for intubation (eg, respiratory failure, inability to control secretions); some of the patients may have been intubated prophylactically out of concern for impending respiratory failure with consequent overestimation of the severity of their clinical presentation. Abstracted articles varied in length and inconsistently reported presence or absence of signs and symptoms. The low completeness score highlights this limitation-approximately two-thirds of cases were rated as "somewhat detailed" or "cursory. " Restricting this systematic review to English language articles may be a limitation, although the abstraction of data from patients in 31 countries may have mitigated this limitation. Authors may have preferentially reported atypical, rare, or severe cases. Finally, confounding factors, such as chronic medical conditions that may predispose to respiratory failure or death, were often not reported and therefore could not be controlled for in the analysis.
In summary, our review documented a range of signs and symptoms at hospital admission, ranging from gastrointestinal symptoms only to cranial nerve palsies, extremity weakness, and respiratory failure. Clinicians should consider botulism in patients with cranial nerve signs or symptoms and evaluate such patients for descending (ie, proximal to distal) weakness and respiratory involvement. When evaluating a suspected noninfant botulism patient in the United States, clinicians should immediately contact CDC through the local or state health department for a clinical consultation to help determine the likelihood of botulism and the need for botulinum antitoxin. Respiratory monitoring using metrics such as vital capacity or negative inspiratory force should be instituted for patients with suspected botulism [1] . We observed that most patients presented to a hospital within 48 hours of illness onset and that most patients requiring intubation were intubated during the first 2 days of hospitalization. Therefore, in planning the response to botulism outbreaks and bioterrorism events, hospitals and public health authorities may anticipate an early peak of similarly severely ill patients in the case of a point-source exposure. The sparsity and poor quality of published data highlight the need for prospective collection of clinical data in future botulism patients, particularly in botulism outbreaks and bioterrorism events.
Supplementary Data
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